Recent advances in anticoagulant drug delivery
Authors:
- 16 December 2015
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Drug Delivery
- Vol. 13 (3) , 421-434
Abstract
Introduction: Anticoagulants have been prescribed to patients to prevent deep vein thrombosis or pulmonary embolism. However, because of several problems in anticoagulant therapy, much attention has been directed at developing an ideal anticoagulant, and numerous attempts have been made to develop new anticoagulant delivery systems in recent years.Areas covered: This review discusses the challenges associated with the recent development of anticoagulants and their delivery systems. Various delivery methods have been developed to improve the use of anticoagulants. Recent advances in anticoagulant delivery and antidote development are also discussed in the context of their current progression states.Expert opinion: There have been many different approaches to developing the delivery system of anticoagulants. One approach has been to expand the use of new oral agents and develop their antidotes. Reducing the size of heparins to use smaller heparins for delivery, and developing oral or topical heparin...Keywords
This publication has 134 references indexed in Scilit:
- Evolution of heparin anticoagulants to ultra-low-molecular-weight heparins: A review of pharmacologic and clinical differences and applications in patients with cancerCritical Reviews in Oncology/Hematology, 2013
- Oral drug delivery systems using chemical conjugates or physical complexesAdvanced Drug Delivery Reviews, 2013
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- A common standard is inappropriate for determining the potency of ultra low molecular weight heparins such as semuloparin and bemiparinThrombosis Research, 2011
- Inhalable Liposomes of Low Molecular Weight Heparin for the Treatment of Venous ThromboembolismJournal of Pharmaceutical Sciences, 2010
- Dendrimers as a Carrier for Pulmonary Delivery of Enoxaparin, a Low-Molecular Weight HeparinJournal of Pharmaceutical Sciences, 2007
- Apical Sodium Dependent Bile Acid Transporter (ASBT, SLC10A2): A Potential Prodrug TargetMolecular Pharmaceutics, 2006
- Low molecular weight heparin and radical prostatectomy: a prospective analysis of safety and side effectsProstate Cancer and Prostatic Diseases, 1997
- Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolismThe Lancet, 1992
- Structure-activity relationship in heparin: A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activityBiochemical and Biophysical Research Communications, 1983